Fibromyalgia Plasma

About Fibromyalgia Plasma

Fibromyalgia Plasma for Chronic Widespread Pain Research

Fibromyalgia Plasma is collected from IRB-consented donors clinically diagnosed with fibromyalgia and processed within hours of collection to preserve cytokines, proteins and metabolites. Fibromyalgia is a chronic widespread pain condition characterised by altered central nociceptive processing — central sensitisation — accompanied by fatigue, sleep disturbance and cognitive symptoms. It is not an autoimmune disease, it is not defined by tissue inflammation, and no blood biomarker has been validated for its diagnosis. That is precisely why well-characterised, clinically annotated plasma is valuable: exploratory work in this area needs cohorts defined by rigorous clinical criteria rather than by an assay.

Why Plasma for Fibromyalgia Research

Because fibromyalgia is diagnosed clinically, plasma studies in this field are hypothesis-generating rather than confirmatory. The most useful specimens are those where the clinical phenotype is documented in enough detail to support careful comparison.

• No validated diagnostic biomarker exists — we state this plainly. Plasma is used here for exploratory discovery and for testing candidate markers against well-defined clinical cohorts, not for classification.
• Clinically defined cohorts are the actual product — fibromyalgia is identified using established criteria based on widespread pain distribution and symptom severity, so plasma linked to those documented assessments is what makes a study interpretable.
• Distinguishing primary from comorbid disease — fibromyalgia frequently co-occurs with rheumatoid arthritis, lupus and Sjögren’s syndrome. Separating donors with fibromyalgia alone from those with a concurrent inflammatory rheumatic disease is essential, because otherwise any inflammatory signal may belong to the comorbid condition.
• Exploratory metabolomics and proteomics — untargeted profiling of small molecules and proteins is an active exploratory approach; anticoagulated plasma is preferred over serum for metabolomics because clotting and platelet release alter the metabolite profile.
• Treatment-annotated comparison — commonly used pharmacotherapies act on central neurotransmitter systems, so plasma from treated versus untreated donors supports pharmacodynamic and drug-exposure research.
• Matched control design — for a condition without a diagnostic assay, carefully matched healthy control plasma processed identically is the single most important element of study design.

Donor Stratification Available

• Diagnostic assessment details: widespread pain and symptom severity scores, or clinical criteria documentation where recorded
• Primary fibromyalgia versus fibromyalgia comorbid with an inflammatory rheumatic disease such as rheumatoid arthritis, lupus or Sjögren’s syndrome
• Symptom duration and reported pain severity or functional impact where recorded
• Current pharmacotherapy: duloxetine or another SNRI, pregabalin or gabapentinoid, tricyclic antidepressant, or no pharmacotherapy
• Comorbid sleep disturbance, mood disorder, irritable bowel syndrome or chronic fatigue where reported
• Age band and sex assigned at birth, for demographically matched cohort construction
• Matched healthy controls available, age- and sex-matched and processed under identical SOPs

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed fibromyalgia donors
• Processed within one day of collection
• Anticoagulant of choice (EDTA, sodium citrate, heparin) available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes reported per lot

De-identified Donor Data

• Verified fibromyalgia diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies and comorbidities
• Symptom duration and clinical assessment details where recorded
• Additional fibromyalgia-specific metadata available on request

Applications

• Exploratory biomarker discovery in chronic widespread pain
• Untargeted and targeted metabolomics
• Proteomic profiling and multiplex panel development
• Comparative studies against matched healthy controls and against inflammatory rheumatic disease cohorts
• Pharmacodynamic and drug-exposure research for centrally acting analgesics
• Assay development and feasibility work for chronic pain programmes
• Multi-cohort study design where fibromyalgia serves as a non-inflammatory pain comparator
• Cell-free DNA and other plasma-specific analyte studies

Other Fibromyalgia Specimen Types

• Fibromyalgia Serum
• Fibromyalgia Whole Blood
• Fibromyalgia PBMC
• Fibromyalgia Leukopak
• Fibromyalgia Bulk Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Fibromyalgia plasma is available in standard and custom volumes. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements to ensure compatibility with your country’s regulations. To browse availability across all disease states, visit our human plasma page.